Korean Drug Co. Ltd (014570) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Korean Drug Co. Ltd stock KRW 8,340, price KRW 2,780, upside +200.0%, quality 72 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 2,780 KRW – 10,389 KRW · fair‑value band 6,338 KRW – 10,342 KRW · the 2,780 KRW price screens below the 8,340 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Korean Drug Co. in your weekly email
Every Wednesday you see whether Korean Drug Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea.
Show moreShow less
The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products.
Korean Drug Co., Ltd. was founded in 1980 and is headquartered in Seoul, South Korea.
Stock analysis
Korean Drug Co. Ltd (014570) currently trades at 2,780 KRW, while our model-based Fair Value estimate is 8,340 KRW, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 14,034 KRW per share, and 22 of the 24 models we run sit above the 2,780 KRW price.
Bear case: the Dividend Discount group reads lowest at 1,840 KRW, and 2 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 6,338 KRW (bear) to 10,342 KRW (bull), the price of 2,780 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Korean Drug Co. Ltd reported revenue of 62.5B KRW in FY2025 versus 74.5B KRW in FY2021, a compound −4.3%/yr. Reported net income was 6.5B KRW in FY2025, compounding −7.9%/yr from FY2021.
Key figures
Market cap 30.1B KRW (≈ $22.3M) Micro · P/E ratio 20.3 · P/S ratio 0.46 · EPS (TTM) 136.86 KRW · Dividend yield 6.5% · Net margin 2.3% · Return on equity 1.9% · Return on assets (EBIT) 13.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 200%, 014570 screens cheaper than that median.
Fair Value models
Bear6,338 KRWFair Value 8,340 KRWBull10,342 KRW
Price 2,780 KRW · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−14.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.3%
Start year 2020 (pandemic). Over 10 years: +2.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+4.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.3%
Dividend (yield on the price)6.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2.3% vs 2.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 11%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score72 · Above median
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)1.9% · Bottom 25%
Return on assets6.9% · Above median
Net margin (12 months)2.3% · Bottom 25%
Operating margin (12 months)15.1% · Below median
Growth and dividend
Revenue growth (quarter YoY)17.6% · Above median
Dividend yield (12 months)6.5% · Top 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Korean Drug Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/014570
Frequently asked questions
Is Korean Drug Co. Ltd (014570) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 8,340 KRW versus a price of 2,780 KRW, about +200% upside (undervalued).
What is the fair value of 014570?
Our model-based fair value for Korean Drug Co. Ltd is 8,340 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 2,780 KRW.
What is the quality score of 014570?
Korean Drug Co. Ltd has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Korean Drug Co. Ltd (014570)?
Our model-based price target is the fair value of 8,340 KRW (as of Nov 3, 2026) from 24 valuation models. Cautious scenario 6,338 KRW, optimistic scenario 10,342 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Korean Drug Co. Ltd stock forecast for 2026?
Our models put fair value at 8,340 KRW, about +200% upside versus a price of 2,780 KRW (undervalued). Cautious scenario 6,338 KRW, optimistic scenario 10,342 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Korean Drug Co. Ltd (014570)?
Korean Drug Co. Ltd reported trailing-twelve-month revenue of about 65.4B KRW (latest available figure, as of Nov 3, 2026).
Does Korean Drug Co. Ltd pay a dividend?
Korean Drug Co. Ltd currently shows a dividend yield of 6.47% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Korean Drug Co. Ltd (014570) and when is the ex-dividend date?
Korean Drug Co. Ltd pays a dividend of 180.00 KRW per share a year, a dividend yield of 6.5%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2001. The payout ratio is 132% of earnings. Free cash flow covers the dividend 6.48 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Korean Drug Co. Ltd (014570)?
For today's price to be fair in a discounted-cash-flow model, Korean Drug Co. Ltd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.3 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 014570 use?
Our models discount Korean Drug Co. Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.23, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Korean Drug Co. Ltd that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Korean Drug Co. Ltd (014570) delivered so far?
Over the past 5 years revenue at Korean Drug Co. Ltd grew -1.3 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Korean Drug Co. Ltd (014570) growing?
The median revenue growth in the sector is +14.3 % a year. That is the yardstick for the growth priced into Korean Drug Co. Ltd (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Korean Drug Co. Ltd (014570)?
The free-cash-flow yield on the price is 41.98 %: that much free cash flow Korean Drug Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Korean Drug Co. Ltd (014570)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Korean Drug Co. Ltd it is 8,340 KRW per share (as of Nov 3, 2026), against a price of 2,780 KRW. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Korean Drug Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 014570 trades below its calculated fair value: price 2,780 KRW, fair value 8,340 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 014570?
No. The price is what the market pays today (2,780 KRW); the fair value is what the company's own numbers justify (8,340 KRW). For Korean Drug Co. Ltd the two are 5,560 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Korean Drug Co. Ltd worth?
The market values Korean Drug Co. Ltd at about 30.1B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 2,780 KRW; our models calculate a fair value of 8,340 KRW per share.
What do the bullish and bearish scenarios say about 014570?
Our models span a range for Korean Drug Co. Ltd: cautious scenario 6,338 KRW, base 8,340 KRW, optimistic 10,342 KRW per share (as of Nov 3, 2026, price 2,780 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 014570?
Korean Drug Co. Ltd trades at a price-to-earnings ratio of 20.3 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 8,340 KRW is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 14.2. Other multiples: P/B 0.4, P/S 0.5, EV/EBITDA 2.6.
How solid is the balance sheet of Korean Drug Co. Ltd (014570)?
Balance-sheet figures for Korean Drug Co. Ltd (as of Nov 3, 2026): return on equity 1.9%. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is 014570 from its 52-week high?
Korean Drug Co. Ltd trades at 2,780 KRW, about 36% below its 52-week high of 4,320 KRW and at the low of 2,780 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 8,340 KRW is for.
Which stocks are comparable to Korean Drug Co. Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Korean Drug Co. Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 2,780 KRW, calculated fair value 8,340 KRW (+200%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 014570 calculated?
We run Korean Drug Co. Ltd through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 8,340 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Korean Drug Co. Ltd currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Korean Drug Co. Ltd (014570)?
The closing price on Nov 6, 2026 was 2,780 KRW. Our model-based fair value is 8,340 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Korean Drug Co. Ltd right now?
The price is below even our cautious bear case (6,338 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (72/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Korean Drug Co. Ltd
How large is the market capitalisation of Korean Drug Co. Ltd (014570)?
The market capitalisation of Korean Drug Co. Ltd is 30.1B KRW (≈ $22.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Korean Drug Co. Ltd (014570)?
The price-to-sales ratio of Korean Drug Co. Ltd is 0.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Korean Drug Co. Ltd (014570)?
Earnings per share at Korean Drug Co. Ltd are 136.86 KRW (price ÷ EPS = P/E 20.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Korean Drug Co. Ltd (014570)?
The dividend yield of Korean Drug Co. Ltd is 6.5% (payout 132%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Korean Drug Co. Ltd (014570)?
The net margin of Korean Drug Co. Ltd is 2.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Korean Drug Co. Ltd (014570)?
The return on equity (ROE) of Korean Drug Co. Ltd is 1.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Korean Drug Co. Ltd (014570)?
On an EBIT basis the return on assets of Korean Drug Co. Ltd is 13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Korean Drug Co. Ltd (014570)?
The operating margin of Korean Drug Co. Ltd is 15.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Korean Drug Co. Ltd (014570)?
Revenue at Korean Drug Co. Ltd is growing +17.6% versus a year earlier (3y avg −7.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Korean Drug Co. Ltd (014570)?
Earnings per share at Korean Drug Co. Ltd are growing +47.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Korean Drug Co. Ltd in the live analysis
One click puts Korean Drug Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026